|1.||Ding, Huanzhong: 3 articles (01/2015 - 01/2014)|
|2.||Green, M J: 3 articles (09/2013 - 05/2009)|
|3.||Bradley, A J: 3 articles (09/2013 - 05/2009)|
|4.||Shan, Q: 2 articles (12/2015 - 04/2014)|
|5.||Shen, Xiangguang: 2 articles (01/2015 - 01/2014)|
|6.||Zhang, Nan: 2 articles (01/2015 - 01/2014)|
|7.||Gu, Xiaoyan: 2 articles (01/2015 - 01/2014)|
|8.||Gu, Mengxiao: 2 articles (01/2015 - 01/2014)|
|9.||Wang, Jing: 2 articles (10/2014 - 06/2014)|
|10.||Shan, Qi: 2 articles (10/2014 - 06/2014)|
11/01/2014 - "Efficacy of standard vs. extended intramammary cefquinome treatment of clinical mastitis in cows with persistent high somatic cell counts."
08/01/2011 - "The objectives of the present study were to evaluate the efficacy of intra-mammary-administered cefquinome for the treatment of sub-clinical mastitis in lactating dairy cows and to determine if extended therapy would enhance treatment efficacy. "
02/01/1997 - "This study supported the efficacy of cefquinome in the treatment of clinical coliform mastitis in dairy cows."
08/01/2013 - "Efficacy of extended cefquinome treatment of clinical Staphylococcus aureus mastitis."
08/01/2011 - "Efficacy of conventional and extended intra-mammary treatment of persistent sub-clinical mastitis with cefquinome in lactating dairy cows."
|2.||Body Weight (Weight, Body)
12/01/2015 - "administration, the corresponding estimates were 6.05 h, 44.39 μg/mL, 0.17 h and 267.8 μg h/mL. The minimum inhibitory concentrations of cefquinome, determined for 30 strains of Streptococcus agalactiae isolated from diseased tilapia, ranged from 0.015 to 0.12 μg/mL. Results from these studies support that 10 mg cefquinome/kg body weight daily could be expected to control tilapia bacterial pathogens inhibited in vitro by a minimal inhibitory concentration value of ≤2 μg/mL. "
12/01/2008 - "A study on bioavailability and pharmacokinetics of cefquinome in piglets was conducted after intravenous (i.v.) and intramuscular (i.m.) administrations of 2.0 mg/kg of body weight, respectively. "
12/01/2015 - "The pharmacokinetics and bioavailability of cefquinome in Beagle dogs were determined by intravenous (IV), intramuscular (IM) or subcutaneous (SC) injection at a single dose of 2 mg/kg body weight (BW). "
10/01/2014 - "The pharmacokinetic (PK) properties of cefquinome were linear over a dose range of 10 to 640 mg/kg of body weight. "
08/01/2014 - "A two-period cross-over study was carried to investigate the pharmacokinetics (PK) and ex-vivo pharmacodynamics (PD) of cefquinome when administrated intravenously (IV) and intramuscularly (IM) in seven healthy dogs at a dose of 2 mg/kg of body weight. "
|3.||Bacterial Infections (Bacterial Infection)
09/01/2009 - "The cefquinome formulation tested was effective and safe in the treatment of severe bacterial infections and septicaemia in foals under field conditions."
09/01/2009 - "A multicentre field study was conducted in accordance with VICH Guideline on Good Clinical Practice (VICH 2000) to confirm the efficacy and safety of a new formulation of cefquinome for the treatment of naturally occurring severe bacterial infections and septicaemia in foals. "
09/01/2009 - "Treatment of septicaemia and severe bacterial infections in foals with a new cefquinome formulation: a field study."
09/01/2009 - "Thirty-nine foals suffering from severe bacterial infections (such as pneumonia, gastro-enteritis, arthritis, omphalitis, or wound infections) or acute septicaemia were treated twice daily with the test product (1 mg cefquinome/kg body weight) intravenously for three days and then intramuscularly for three to 11 days. "
01/01/2015 - "In order to provide some basis for effective dosage regimens that optimize efficacy with respect to bacteriological and clinical cures, the in vivo activity of cefquinome against a clinical Escherichia coli (E.coli) strain (the minimum inhibitory concentration value for this strain equals to the MIC90 value of 0.25 μg/ml for 210 E.coli strains isolated from pigs) was investigated by using a piglet tissue-cage infection model. "
10/01/2014 - "The potent bactericidal activity makes cefquinome an attractive option for the treatment of infections caused by E. "
06/01/2014 - "Pharmacodynamics of cefquinome in a neutropenic mouse thigh model of Staphylococcus aureus infection."
01/01/2014 - "In rats, we evaluated the impact of cefquinome, a fourth-generation cephalosporin, on both Klebsiella pneumoniae lung infection and intestinal flora harboring CTX-M-producing Enterobacteriaceae. "
01/01/2014 - "Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal flora."
01/01/1991 - "The high in vitro activity of cefquinome is reflected by its high in vivo efficacy against experimental septicemia due to different gram-positive and gram-negative bacteria. "
01/01/2015 - "Integration of PK/PD for dose optimization of Cefquinome against Staphylococcus aureus causing septicemia in cattle."
04/01/1999 - "[Effectiveness and disposition of the newly developed cephalosporin cefquinome in puerperal septicemia and toxemia in gilts]."
|6.||Cefoperazone (Cefoperazone Sodium)